NEW POSSIBILITIES OF TREATMENT OF PATIENTS WITH ISHEMIC HEART DISEASE AND STABLE ANGINA

Abstract

Purpose. To e valuate clinical effectiveness of a new dosage form of trimetazidine for a single administration per day (Deprenorm MV 70) in patients with ischemic heart disease (IHD) and stable angina.

Materials and methods. The study included 85 patients with IHD and stable angina. Patients were randomized in groups of trimetazidine administration 70 mg once per day (Deprenorm MV 70) and placebo in addition to the standard therapy. Initially in 1 and 6 months the gravity of IHD in patients was determined with evaluation of the daily frequency of the angina attacks, the number of nitroglycerin tablet consumed per week, the physical activity by a method of bycicle veloergometries with calculation of the threshold power (TP) and the scope of performed work. Additionally evaluation of the anti-oxidative system of the body was performed in groups: concentration of the major lipid endogenous antioxidant α-tocopherol and extracellular antioxidant enzyme – ceruloplasmin.

Results. In the group with use in the therapy of the drug Deprenorm MV 70 1 tpd versus the group without trimetazidine the tolerance to stress was increased and the number of nitroglycerin tablets consumed by patients per week was reduced: by Month 1 – by 61.8%, by Month 6 – by 72.5%. In the group of Deprenorm MV 70 drug a statistically significant increase of TP was observed: in 1 month – by 32.3%, in 6 months – by 37.5% versus the initial level. Deprenorm MV 70 had a positive effect on the lipid peroxidation. Placebo administration didn’t have any effect on the value of the studied indicators.

Conclusion. The obtained data testify about reduction of depth and duration of ischemia on the background of Deprenorm MV 70 (1 tablet 1 tpd) administration in stable angina patients. Application of Deprenorm MV 70 improves the clinical course of angina and increases the anti-angina effectiveness of prolonged nitrates in their long-term use.